The country’s first mRNA-based corona vaccine has been found safe in the first phase of the trial. mRNA vaccines are a new type of vaccine to protect against infectious diseases.mRNA vaccines teach our cells how to make a protein—or even just a piece of a protein—that triggers an immune response inside our bodies. Based on the results of this trial, the Drug Controller General of India has given permission to the Pune-based biotechnology company Gennova Bio Pharmaceuticals Limited, which is working on the vaccine, for Phase II and III clinical trials. The company had sent the interim results of the first phase of its vaccine trial to the subject expert committee of the Central Drug Controller Standard Control Organization. The committee reviewed the interim outcome data of the first phase of the vaccine and found the vaccine to be safe and immunogenic. After this, the second and third phase human trials were allowed. In this study, Gennova will use DBT- ICMR clinical trials network sites. Gennova’s vaccine development program is being funded by the Department of Biotechnology. Later, the Department of Biotechnology supported the program under Mission Covid Suraksha – Indian Covid-19 Vaccine Development Mission. On getting permission for the second and third phases of the vaccine, Department of Biotechnology Secretary Renu Swarup said that it is a matter of pride that the country’s first mRNA-based vaccine has been found to be safe.
